Re-release of Drug Watch guidance
Executive Summary
FDA expects to release its revised Drug Watch guidance "very soon," according to CDER Director Steven Galson. "We're very close to completing the guidance that responds to the initial draft we put out and comes up with decisions on each of those questions that were raised," Galson says Sept. 22. The original plans for a website for posting emerging risk information drew intense criticism, prompting FDA to redraft the guidance (1"The Pink Sheet" Feb. 21, 2006, p. 5)...
You may also be interested in...
Boxed Warnings, Drug Watch Are Policy Goals Of Drug Safety Oversight Board
FDA's Drug Safety Oversight Board should start shifting its focus toward broader policy questions - like standards for boxed warnings - in addition to addressing emerging safety issues for specific products, DSOB Executive Director Susan Cummins suggested
Vertex’s Price Tag For Taking More Control Of CRISPR-Partnered Candidate: At Least $900m
Vertex and partner CRISPR Therapeutics hope CDX001 can offer a single-use curative regimen for sickle cell disease and beta thalassemia patients. A regulatory filing is possible within 18-24 months.
J&J’s Consumer Health Product Sales Slump In Comparison A Year After COVID-19 Stockpiling
Worldwide consumer health sales in January-March period were down 3.3% to $3.5bn with results off 7.4% to $1.6bn in the US and up 0.5% to $1.9bn internationally. However, excluding “COVID-19 comparison” in the year-ago period, the consumer health segment grew low-single-digits.